Empagliflozin and 12-Month Clinical Outcomes in Patients with Heart Failure with Preserved Ejection Fraction: A Prospective Observational Cohort Study in Pakistan
Pakistan Heart Journal · 31.10.2026 · 59 (5) · 1366-1376
DOI: 10.47144/phj.v59i5.3905 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Pakistan Heart Journal, online erschienen am 31.10.2026. Verfasst von Raffat Sultana und 6 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Objectives
To evaluate the association of empagliflozin 10 mg once daily with first heart failure (HF) hospitalization among Pakistani adults with heart failure with preserved ejection fraction (HFpEF), and to assess its associations with cardiovascular mortality, renal function, health-related quality of life, and safety during 12 months of follow-up. Methodology: This prospective, single-center observational cohort study included 400 adults with symptomatic HFpEF enrolled at the Karachi Institute of Heart Diseases. Participants were categorized into an empagliflozin group (n=200), receiving empagliflozin 10 mg/day in addition to standard heart failure therapy, and a control group (n=200), receiving standard therapy without an SGLT2 inhibitor. Treatment allocation was non-randomized and reflected routine clinical prescribing. Definite HFpEF was defined by LVEF ≥50%, NYHA class II–IV symptoms, elevated NT-proBNP, and echocardiographic evidence of structural and/or diastolic dysfunction. The primary outcome was first unplanned HF hospitalization during 12 months. Secondary outcomes included all-cause mortality, change in eGFR, and KCCQ-12 score.
Results
5 patients (2.5%) in the empagliflozin group and 7 (3.5%) in the control group lost to follow-up. First HF hospitalization occurred in 36 patients (18.0%) in empagliflozin compared with 60 patients (30.0%) in the control group. After multivariable adjustment, empagliflozin use was associated with a lower hazard of first HF hospitalization (adjusted HR 0.58, 95% CI 0.39–0.86; p=0.007). Cardiovascular mortality occurred in 12 (6.0%) versus 18 (9.0%) patients, respectively, with no statistically significant between-group association (adjusted HR 0.67, 95% CI 0.32–1.39; p=0.28). The annualized eGFR slope was −2.5 mL/min/1.73 m²/year in the empagliflozin group compared with −6.4 mL/min/1.73 m²/year in controls, with an adjusted between-group difference at 12 months of +3.9 mL/min/1.73 m² (95% CI 2.1–5.7; p
Zitieren
APA
Sultana, R., Sultana, N., Jaffery, S., Haq, A. U., Jamal, A., Ahmed, M., & Ishaq, M. (2026). Empagliflozin and 12-Month Clinical Outcomes in Patients with Heart Failure with Preserved Ejection Fraction: A Prospective Observational Cohort Study in Pakistan. Pakistan Heart Journal, 59(5), 1366-1376. https://doi.org/10.47144/phj.v59i5.3905
Vancouver
Sultana R, Sultana N, Jaffery S, Haq AU, Jamal A, Ahmed M, et al. Empagliflozin and 12-Month Clinical Outcomes in Patients with Heart Failure with Preserved Ejection Fraction: A Prospective Observational Cohort Study in Pakistan. Pakistan Heart Journal. 2026;59(5):1366-1376. doi:10.47144/phj.v59i5.3905
BibTeX
@article{Sultana2026,
author = {Sultana, Raffat and Sultana, Nuzhat and Jaffery, Saqib and Haq, Amir Ul and Jamal, Asim and Ahmed, Mansoor and Ishaq, Muhammad},
title = {Empagliflozin and 12-Month Clinical Outcomes in Patients with Heart Failure with Preserved Ejection Fraction: A Prospective Observational Cohort Study in Pakistan},
journal = {Pakistan Heart Journal},
year = {2026},
volume = {59},
number = {5},
pages = {1366--1376},
doi = {10.47144/phj.v59i5.3905}
}
EUVIMED